Ultragenyx Pharmaceutical (RARE) FCF Margin (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly FCF Margin of 145.59% for Q1 2026, down 2544.0% year-over-year from 5.96% in Q1 2025, and down 199.48% quarter-over-quarter from 48.61% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) FCF Margin (2016 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported FCF Margin for 11 consecutive years, with 145.59% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 2544.0% year-over-year to 145.59%; the TTM figure through Mar 2026 stood at 75.11% (down 665.0% YoY), while the FY2025 annual figure was 70.13%, up 647.0% from the prior year.
- FCF Margin eased to 145.59% in Q1 2026 per RARE's latest filing, from 48.61% in the prior quarter.
- Across five years, FCF Margin topped out at 40.45% in Q4 2023 and bottomed at 187.28% in Q1 2022.
- Historically, FCF Margin has averaged 105.01% across 5 years, with a median of 120.12% in 2023.
- Annual changes were most pronounced in 2022 — FCF Margin plunged 16047 bps — and 2023, when it jumped 13955 bps.
- Ultragenyx Pharmaceutical's FCF Margin stood at 180.0% in 2022, then soared by 78 bps to 40.45% in 2023, then sank by 31 bps to 53.13% in 2024, then gained by 9 bps to 48.61% in 2025, then slumped by 199 bps to 145.59% in 2026.
- Business Quant data shows RARE's FCF Margin at 145.59% in Q1 2026, 48.61% in Q4 2025, and 57.96% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | -45.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.79% |
| Mar 31, 2026 | -145.59% |
| Dec 31, 2025 | -48.61% |
| Sep 30, 2025 | -57.96% |
| Jun 30, 2025 | -66.99% |
| Mar 31, 2025 | -120.14% |
| Dec 31, 2024 | -53.13% |
| Sep 30, 2024 | -52.28% |
| Jun 30, 2024 | -52.09% |
| Mar 31, 2024 | -176.42% |
| Dec 31, 2023 | -40.45% |
| Sep 30, 2023 | -123.98% |
| Jun 30, 2023 | -120.12% |
| Mar 31, 2023 | -181.00% |
| Dec 31, 2022 | -180.00% |
| Sep 30, 2022 | -58.07% |
| Jun 30, 2022 | -121.08% |
| Mar 31, 2022 | -187.28% |
| Dec 31, 2021 | -19.54% |
| Sep 30, 2021 | -98.24% |